nubia Unveils Pad Pro, Designed for Work, Study and Entertainment
SHENZHEN, China, June 12, 2025 /PRNewswire/ — nubia has launched its first-ever tablet – the nubia Pad Pro. Designed to meet the growing demands of users across work, study, and entertainment, the nubia Pad Pro delivers a high-performance experience powered by the Qualcomm Snapdragon® 8 Gen 3 processor, featuring a Prime Cortex-4 clock speed at up to 3.3GHz.
It's equipped with LPDDR5X high-speed memory and UFS4.0 flash storage, ensuring smooth multitasking capabilities and fast load times across applications. The nubia Pad Pro features a 10.9-inch 2.8K ultra-clear true-color screen with a resolution of 2880×1800, offering vivid visuals and accurate color reproduction. For audio, it supports DTS X® Ultra spatial 3D sound, creating an immersive stereo experience ideal for entertainment and content consumption.
Built with an aerospace-grade unibody metal chassis, the nubia Pad Pro weighs just 523g and is only 7.3mm thin. Its 45° anti-slip tilt design enhances grip and stability, making it comfortable to carry and use on the go. A 20MP front HD camera provides clear, high-quality video for calls and conferencing, while the 78-key full-function keyboard layout delivers a laptop-like typing experience for smooth writing and productivity.
The nubia Pad Pro is a smart, powerful companion device that blends mobility, performance, and premium design — setting a strong foundation for nubia's expansion into the tablet space.
Pricing and Availability:
nubia Pad Pro:
For the 8GB+256GB variant: $419 GL , £359 in the UK, and €419 in the EU.
For the 12GB+256GB variant: $489 GL, £429 in the UK, and €489 in the EU.
For the 16GB+512GB variant: $599 GL, £499 in the UK, and €579 in the EU.
Here are the relevant URLs:
Global: https://intl.nubia.com/ EU: https://eu.nubia.com/ UK: https://uk.nubia.com/ Mexico: https://mx.nubia.com/
About nubia
Founded in October 2012, nubia aims to bring high-end innovative smartphones to adventurous users who want to pursue new experiences and an enhanced quality of life. Inspiring the world to 'Be yourself,' nubia continues to elevate lifestyles by encouraging users to chase their dreams and pursue new passions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years. 'We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,' said Dr. Helen Torley, president and chief executive officer of Halozyme. The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the study and its findings, please view argenx's press release issued on June 20, 2025. The approval by the EC is valid in all 27 European Union (EU) Member States, as well as Iceland, Norway and Liechtenstein. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding potential growth catalysts and opportunities driven by the product development and commercialization efforts of Halozyme's ENHANZE® partners. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning unexpected results or delays in the timing of the Halozyme's expected growth catalysts or in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney CharltonTeneo 917-972-8407
Malaysian Reserve
2 days ago
- Malaysian Reserve
Johnson Pope Expands Legal Talent with the Addition of Jessica Warwick and Samuel C. Craig to Its St. Petersburg Office
ST. PETERSBURG, Fla., June 20, 2025 /PRNewswire/ — Johnson, Pope, Bokor, Ruppel & Burns, LLP is proud to announce the addition of two new associate attorneys, Jessica Warwick and Samuel C. Craig, to its St. Petersburg office. These strategic hires reflect the firm's continued growth and commitment to serving clients with deep, specialized knowledge across key practice areas. Jessica Warwick Joins Healthcare Practice GroupJessica Warwick has joined Johnson Pope's Healthcare Practice Group, where she advises hospitals, health systems, and medical providers on a wide range of regulatory and compliance matters. Her areas of focus include telemedicine, the corporate practice of medicine, and Medicare/Medicaid compliance. Jessica holds both a Juris Doctor and a Master of Health Administration from Penn State. Her experience includes drafting and negotiating management and professional services agreements, conducting regulatory compliance reviews for digital health platforms, and supporting healthcare M&A transactions. Jessica is admitted to the Florida Bar and currently serves as the Health and Wellness Chair for the Pinellas County chapter of the Florida Association for Women Lawyers. Samuel C. Craig Joins Tax, Trusts & Estates Practice GroupsSamuel C. Craig has joined Johnson Pope as an associate in the Tax, Trusts & Estates and Business Transactions Practice Groups. Sam focuses his practice on estate planning, tax law, and business matters, providing practical, strategic counsel to individuals, families, and business owners. Sam earned his J.D. from Stetson University College of Law, where he was a research assistant, president of the Business Law Society, and a member of both the Dispute Resolution Board and Trial Team. He received multiple awards for oral advocacy, including a national mock trial championship and induction into the National Order of the Barristers. He later earned his LL.M. in Taxation from the University of Florida on a merit scholarship where he earned multiple CALI book awards, further honing his knowledge of federal and state tax law. Sam is dedicated to helping clients protect their legacies, minimize tax burdens, and navigate complex legal issues with clarity and care. About Johnson PopeJohnson, Pope, Bokor, Ruppel & Burns, LLP is a full-service Florida-based law firm with offices in Tampa, Clearwater, and St. Petersburg. The firm is known for its commitment to excellence, innovative legal solutions, and deep roots in the communities it serves. To learn more, visit
Malaysian Reserve
2 days ago
- Malaysian Reserve
Outdated Inventory Systems Are Costing Retailers: Info-Tech Research Group Publishes Insights on How AI Can Make a Difference
Global research and advisory firm Info-Tech Research Group has published new research insights to help retailers leverage AI effectively amidst evolving supply chain and inventory management challenges. The firm's resource walks retail industry IT leaders through seven steps to develop AI strategies that optimize stock levels, streamline operations, and respond faster to market changes. TORONTO, June 20, 2025 /PRNewswire/ – Inventory has become one of retail's most expensive guessing games. As customer expectations evolve faster than supply chains can respond, retailers are often stuck choosing between empty shelves and excess stock, both of which erode margins. In response to these growing industry challenges for organizations and their IT teams, Info-Tech Research Group has published Build Your AI Strategy for Retail Inventory Management, a practical blueprint that helps retailers transition from outdated inventory methods to intelligent, data-driven operations. The global research and advisory firm's new resource outlines how industry IT leaders can apply AI to improve forecasting, optimize stock levels, and deliver measurable performance gains. Adoption Challenges Are Slowing AI Integration in Retail Inventory Systems Info-Tech reports in its recently published resource that despite the clear benefits of AI in transforming retail inventory management, many organizations face significant challenges in adoption. The firm's research insights highlight that aligning the business stakeholders to develop a cohesive AI strategy remains a common hurdle, especially when it involves addressing existing inventory limitations and identifying critical gaps. Additionally, realizing AI's full potential often requires mature data infrastructure and advanced system capabilities that not all retailers have in place. 'Inventory management applications that are AI-driven can deliver where traditional inventory management falls short,' says Donnafay MacDonald, research director at Info-Tech Research Group. 'By providing real-time insights backed by big data, these applications enable retailers to respond to market changes through predictive forecasts that reduce waste, improve operational efficiency, and enhance customer satisfaction.' Info-Tech Recommends a Seven-Step AI Implementation Framework for Retail IT Leaders To support IT and business leaders in overcoming these barriers, Info-Tech offers a clear, step-by-step framework featuring a practical use-case library. The blueprint outlines seven key steps to guide retail IT leaders in developing and executing an AI strategy tailored to their inventory needs. These include: Formulating an AI strategy aligned to business goals. Define how AI will drive key objectives such as boosting customer satisfaction, cutting costs, or increasing agility and set clear success metrics. Establishing responsible AI principles. Put ethical, privacy, and governance guardrails in place to ensure transparent, fair, and secure AI solutions. Launching targeted AI initiatives. Start with pilots such as demand forecasting or automated replenishment to prove value and build momentum. Building a use case library. Catalog specific applications such as dynamic pricing or shelf space optimization with defined benefits, data needs, and technical requirements. Evaluating value and feasibility. Estimate ROI, resource demands, and risks for each use case to spotlight quick wins and flag longer term projects. Prioritizing projects. Rank initiatives by impact, effort, and risk so teams invest where they will see the fastest, biggest returns. Mapping out an AI roadmap. Sequence pilots and rollouts with clear milestones for data readiness, model validation, and performance reviews. InfoTech advises that by addressing longstanding challenges in inventory management, retailers have an opportunity to adopt smarter, more resilient systems that reflect the realities of today's retail environment. With competitors already incorporating AI into their everyday operations, the pressure to evolve is intensifying for IT leaders. The firm's blueprint provides retailers with straightforward, actionable guidance to implement AI in a way that supports business goals without adding unnecessary complexity. Info-Tech explains that with the right tools and direction, retailers can improve product availability, streamline operations, and respond to demand shifts with greater confidence and control. For exclusive and timely commentary from Donnafay MacDonald, an expert in the retail sector, and access to the complete Build Your AI Strategy for Retail Inventory Management blueprint, please contact pr@ About Info-Tech Research GroupInfo-Tech Research Group is one of the world's leading research and advisory firms, serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@ For information about Info-Tech Research Group or to access the latest research, visit and connect via LinkedIn and X.
